Israeli Laboratory of Experimental Medicine (LEM) has begun conducting a one-of-a-kind molecular analysis called Prosigna™ test, the purpose of which is to evaluate the likelihood of cancer recurrence. It is based on an algorithm, which is calculated accordance to following criteria:
Multiple studies, clinical trials' results and publications in scientific journals support the importance of gene expression analysis for the purpose of classifying breast cancer, in order to determine prognosis and optimal course of treatment in early-stage breast cancer patients.
The test is performed using the advanced nCounter system, manufactured by Seattle-based NanoString Technology, a company that specializes in development of molecular-genetic tests and diagnostics tools.
The Prosigna™ test is considered to have the following advantages over other prognostic tests for breast cancers:
It is important to note that:
The Prosigna™ test is intended for female patients, who were diagnosed with early-stage receptor-positive breast cancer and had undergone either a mastectomy or an organ-sparing operation (lumpectomy).